| Literature DB >> 28702076 |
Massimo Sartelli1, Alain Chichom-Mefire2, Francesco M Labricciosa3, Timothy Hardcastle4, Fikri M Abu-Zidan5, Abdulrashid K Adesunkanmi6, Luca Ansaloni7, Miklosh Bala8, Zsolt J Balogh9, Marcelo A Beltrán10, Offir Ben-Ishay11, Walter L Biffl12, Arianna Birindelli13, Miguel A Cainzos14, Gianbattista Catalini1, Marco Ceresoli7, Asri Che Jusoh15, Osvaldo Chiara16, Federico Coccolini7, Raul Coimbra17, Francesco Cortese18, Zaza Demetrashvili19, Salomone Di Saverio13, Jose J Diaz20, Valery N Egiev21, Paula Ferrada22, Gustavo P Fraga23, Wagih M Ghnnam24, Jae Gil Lee25, Carlos A Gomes26, Andreas Hecker27, Torsten Herzog28, Jae Il Kim29, Kenji Inaba30, Arda Isik31, Aleksandar Karamarkovic32, Jeffry Kashuk33, Vladimir Khokha34, Andrew W Kirkpatrick35, Yoram Kluger36, Kaoru Koike37, Victor Y Kong38, Ari Leppaniemi39, Gustavo M Machain40, Ronald V Maier41, Sanjay Marwah42, Michael E McFarlane43, Giulia Montori7, Ernest E Moore44, Ionut Negoi45, Iyiade Olaoye46, Abdelkarim H Omari47, Carlos A Ordonez48, Bruno M Pereira23, Gerson A Pereira Júnior49, Guntars Pupelis50, Tarcisio Reis51, Boris Sakakhushev52, Norio Sato53, Helmut A Segovia Lohse40, Vishal G Shelat54, Kjetil Søreide55,56, Waldemar Uhl28, Jan Ulrych57, Harry Van Goor58, George C Velmahos59, Kuo-Ching Yuan60, Imtiaz Wani61, Dieter G Weber62, Sanoop K Zachariah63, Fausto Catena64.
Abstract
Intra-abdominal infections (IAIs) are common surgical emergencies and have been reported as major contributors to non-trauma deaths in the emergency departments worldwide. The cornerstones of effective treatment of IAIs are early recognition, adequate source control, and appropriate antimicrobial therapy. Prompt resuscitation of patients with ongoing sepsis is of utmost important. In hospitals worldwide, non-acceptance of, or lack of access to, accessible evidence-based practices and guidelines result in overall poorer outcome of patients suffering IAIs. The aim of this paper is to promote global standards of care in IAIs and update the 2013 WSES guidelines for management of intra-abdominal infections.Entities:
Keywords: Antibiotics; Intra-abdominal infections; Peritonitis; Sepsis
Mesh:
Substances:
Year: 2017 PMID: 28702076 PMCID: PMC5504840 DOI: 10.1186/s13017-017-0141-6
Source DB: PubMed Journal: World J Emerg Surg ISSN: 1749-7922 Impact factor: 5.469
Grading of Recommendations Assessment, Development and Evaluation (GRADE) hierarchy of evidence from Guyatt et al. [9]
| Grade of recommendation | Clarity of risk/benefit | Quality of supporting evidence | Implications |
|---|---|---|---|
| 1A | |||
| Strong recommendation, high-quality evidence | Benefits clearly outweigh risk and burdens, or vice versa | RCTs without important limitations or overwhelming evidence from observational studies | Strong recommendation, applies to most patients in most circumstances without reservation |
| 1B | |||
| Strong recommendation, moderate-quality evidence | Benefits clearly outweigh risk and burdens, or vice versa | RCTs with important limitations (inconsistent results, methodological flaws, indirect analyses, or imprecise conclusions) or exceptionally strong evidence from observational studies | Strong recommendation, applies to most patients in most circumstances without reservation |
| 1C | |||
| Strong recommendation, low-quality, or very low-quality evidence | Benefits clearly outweigh risk and burdens, or vice versa | Observational studies or case series | Strong recommendation but subject to change when higher quality evidence becomes available |
| 2A | |||
| Weak recommendation, high-quality evidence | Benefits closely balanced with risks and burden | RCTs without important limitations or overwhelming evidence from observational studies | Weak recommendation, best action may differ depending on the patient, treatment circumstances, or social values |
| 2B | |||
| Weak recommendation, moderate-quality evidence | Benefits closely balanced with risks and burden | RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies | Weak recommendation, best action may differ depending on the patient, treatment circumstances, or social values |
| 2C | |||
| Weak recommendation, low-quality, or very low-quality evidence | Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced | Observational studies or case series | Very weak recommendation; alternative treatments may be equally reasonable and merit consideration |
SOFA Score
| PaO2/FiO2 (mmHg) | SOFA score |
|---|---|
| <400 | 1 |
| <300 | 2 |
| <200 and mechanically ventilated | 3 |
| <100 and mechanically ventilated | 4 |
| Glasgow coma scale | |
| 13–14 | 1 |
| 10–12 | 2 |
| 6–9 | 3 |
| <6 | 4 |
| Mean arterial pressure OR administration of vasopressors required | SOFA score |
| MAP <70 mm/Hg | 1 |
| dop ≤5 or dob (any dose) | 2 |
| dop >5 OR epi ≤0.1 OR nor ≤0.1 | 3 |
| dop >15 OR epi >0.1 OR nor >0.1 | 4 |
| Bilirubin (mg/dl) [μmol/L] | |
| 1.2–1.9 [>20–32] | 1 |
| 2.0–5.9 [33–101] | 2 |
| 6.0–11.9 [102–204] | 3 |
| >12.0 [>204] | 4 |
| Platelets × 103/μl | |
| <150 | 1 |
| <100 | 2 |
| <50 | 3 |
| <20 | 4 |
| Creatinine (mg/dl) [μmol/L] (or urine output) | |
| 1.2–1.9 [110–170] | 1 |
| 2.0–3.4 [171–298, 305] | 2 |
| 3.5–4.9 [300–440] (or <500 ml/d) | 3 |
| >5.0 [>440] (or <200 ml/d) | 4 |
Source of infection in 4553 patients from 132 hospitals worldwide (15 October 2014–2015 February 2015) [1]
| Source of infection | Number (%) |
|---|---|
| Appendicitis | 1553 (34.2) |
| Cholecystitis | 837 (18.5) |
| Post-operative | 387 (8.5) |
| Colonic non-diverticular perforation | 269 (5.9) |
| Gastro-duodenal perforations | 498 (11) |
| Diverticulitis | 234 (5.2) |
| Small bowel perforation | 243 (5.4) |
| Others | 348 (7.7) |
| PID | 50 (1.1) |
| Post traumatic perforation | 114 (2.5) |
| Total | 4553 (100) |
Antibiotics for treating patients with IAIs based upon susceptibility [253]
| Antibiotic | Enterococci | Ampicillin-resistant enterococci | Vancomycin-resistantenterococci |
| ESBL-producing |
| Anaerobic gram-negative bacilli |
|---|---|---|---|---|---|---|---|
| Penicillins/beta-lactamase inhibitors | |||||||
| Amoxicillin/clavulanate | + | − | − | + | − | − | + |
| Ampicillin/sulbactam | + | − | − | + | − | − | +/− |
| Piperacillin/tazobactam | + | − | − | + | +/− | + | + |
| Carbapenems | |||||||
| Ertapenem | − | − | − | + | + | − | + |
| Imipenem/cilastatin | +/−a | − | − | + | + | + | + |
| Meropenem | − | − | − | + | + | + | + |
| Doripenem | − | − | − | + | + | + | + |
| Fluoroquinolones | |||||||
| Ciprofloxacin | − | − | − | + | − | +b | − |
| −−Levofloxacin | +/− | − | − | + | − | +/− | − |
| Moxifloxacin | +/− | − | − | + | − | − | +/− |
| Cephalosporins | |||||||
| Ceftriaxone | − | − | − | + | − | − | − |
| Ceftazidime | − | − | − | + | − | + | − |
| Cefepime | − | − | − | + | +/− | + | − |
| Ceftozolane/tazobactam | − | − | − | + | + | + | − |
| Ceftazidime/avibactam | − | − | − | + | + | + | − |
| Aminoglycosides | |||||||
| Amikacin | + | + | + | − | |||
| Gentamicin | + | + | + | − | |||
| Glycylcyclines | |||||||
| Tigecycline | + | + | + | +c | + | − | + |
| 5-Nitroimidazole | |||||||
| Metronidazole | + | ||||||
| Polymixyn | |||||||
| Colistimethate | − | − | − | +d | + | + | − |
| Glycopeptides | |||||||
| Teicoplanin | + | + | − | − | − | − | − |
| Vancomycin | + | + | − | − | − | − | − |
| Oxazolidines | |||||||
| Linezolid | + | + | + | − | − | − | − |
aImipenem/cilastatin is more active against ampicillin-susceptible enterococci than ertapenem, meropen and doripenem
bCiprofloxacin is more active against P. aeruginosa than levofloxacin
cNot active against Proteus, Morganella, and Providencia
dNot active against Morganella, Proteus, Providencia, Salmonella, Serratia, Shigella, and Yersina (Y. enterocolitica)
Antibiotics commonly used to treat biliary tract infections and their biliary penetration ability [153]
| Good penetration efficiency | Low penetration efficiency |
|---|---|
| Piperacillin/tazobactam | Ceftriaxone |
| Tigecycline | Cefotaxime |
| Amoxicillin/clavulanate | Meropenem |
| Ciprofloxacin | Ceftazidime |
| Ampicillin/sulbactam | Vancomycin |
| Cefepime | Amikacin |
| Levofloxacin | Gentamicin |
| Imipenem |